Combination Chemotherapy and Translational Inhibitors

Doxorubicin, Gemcitabine, Paclitaxel, Cytarabine (AraC) (Kojima et al., 2005 (link)), Trazodone, and Trans-ISRIB (Costa-Mattioli and Walter, 2020 ; Zyryanova et al., 2021 (link)), were obtained from Cayman Chemicals and used as described. Sal003 10uM was obtained from selleckchem. Cells were treated with 1 μM Trans-ISRIB or 5 μM Trazodone for 18–24 h. For cell viability that was measured by Trypan blue staining and cell counts (Lee et al., 2020 (link)), cells were treated individually or with a combination of chemotherapies and 1 μM Trans-ISRIB or trazodone for 18–24 h.

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Bukhari S.I., Truesdell S.S., Datta C., Choudhury P., Wu K.Q., Shrestha J., Maharjan R., Plotsker E., Elased R., Laisa S., Bhambhani V., Lin Y., Kreuzer J., Morris R., Koh S.B., Ellisen L.W., Haas W., Ly A, & Vasudevan S. (2023). Regulation of RNA methylation by therapy treatment, promotes tumor survival. bioRxiv.

Publication Preprint 2023

Doxorubicin Gemcitabine Paclitaxel Cytarabine Trans-ISRIB Sal003

Arac Cayman Cell viability Cells Combination chemotherapies Costa Cytarabine Doxorubicin Gemcitabine Paclitaxel Trans isrib Trazodone Trypan blue

Corresponding Organization : Massachusetts General Hospital

Top 5 similar protocols

Variable analysis

independent variables

Doxorubicin
Gemcitabine
Paclitaxel
Cytarabine (AraC)
Trazodone
Trans-ISRIB
Sal003 10uM

dependent variables

Cell viability measured by Trypan blue staining and cell counts

control variables

Cells were treated individually or with a combination of chemotherapies and 1 μM trans-ISRIB or trazodone for 18–24 h

controls

Positive control: Not specified
Negative control: Not specified

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!